Polyplus acquires Bio Elpida, a French biotechnology contract development and manufacturing (CDMO) company to strengthen the supply chain for GMP formulation and filling at Polyplus.
Strasbourg, France, December 14th 2022 – Polyplus, a leading solutions provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, has completed the acquisition of Bio Elpida, a French biotechnology contract development and manufacturing (CDMO) company providing pre-clinical and clinical development services for cell therapy and biologics. The teams will integrate strategically to strengthen the supply chain for GMP formulation and filling at Polyplus.
“Bio Elpida is certified by the French Health Authorities (ANSM) as a Pharmaceutical Company to manufacture Active Pharmaceutical Ingredients and Advanced Therapy Medicinal Product. Our team feels proud to support innovative cell therapy development with capacity and expertise for projects from proof-of-concept studies to the clinic. As demand continues to increase for GMP development and manufacturing support, we are looking to take the next step forward by integrating with a leading supplier to deepen our impact on the industry,” CEO of Bio Elpida, Julien Gillet-Daubin, commented.
“There is an increased demand for higher quality raw materials for Cell & Gene Therapy Manufacturing with increased regulatory scrutiny. Across modalities, we see that using scalable technologies and products to develop reliable processes from the start is most effective way to achieve commercialization success,” said CEO of Polyplus, Mario Philips. “We will continue evolving the Polyplus portfolio of products and services with a scalable foundation, including GMP manufacturing capacity, to optimize upstream process economics for each customers’ unique process.”
Existing cell therapy and fill and finish CDMO services will continue to be offered and developed, while leveraging fill and finish capacity to support Polyplus growth and customer needs for GMP grade transfection reagents. A network of external fill and finish partners will also be maintained for full business continuity.
About Bio Elpida
Bio Elpida is a CDMO offering bespoke pre-clinical and clinical development services focused on Innovative cell therapy projects. Company has continuously expanded its expertise and know-how in the development of bioprocesses and GMP production of clinical batches for innovative cell and gene therapy projects since 2009. Bio Elpida’s team of experts provides agile and tailored approaches to achieve development and manufacturing, cell banking or aseptic fill and finish processes. Additionally, Bio Elpida completes its offer with an extensive set of analytics, end-to-end quality control management and quality-by-design approach. Learn more at www.bio-elpida.com.
Polyplus is a leading upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services including bioproduction industry standard, PEIpro® and FectoVIR®-AAV. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help the industry optimize process economics while meeting strict scientific and regulatory standards. Headquartered in Europe, the Polyplus team continues to grow globally with operations in the United States and Asia.
Media Contact Information:
Alengo Nyamay’antu, PhD
Marketing & Communication team leader at Polyplus
Direct: +33 3 88 67 59 38